Generali Asset Management SPA SGR Invests $4.04 Million in Hologic, Inc. (NASDAQ:HOLX)

Generali Asset Management SPA SGR bought a new position in Hologic, Inc. (NASDAQ:HOLX) in the fourth quarter, according to the company in its most recent filing with the SEC. The fund bought 56,040 shares of the medical equipment provider’s stock, valued at approximately $4,040,000.

A number of other institutional investors and hedge funds have also recently modified their holdings of HOLX. First Horizon Advisors Inc. lifted its stake in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after acquiring an additional 134 shares during the last quarter. Brooklyn Investment Group raised its position in Hologic by 14.7% during the 4th quarter. Brooklyn Investment Group now owns 1,131 shares of the medical equipment provider’s stock valued at $82,000 after purchasing an additional 145 shares in the last quarter. Smartleaf Asset Management LLC raised its position in Hologic by 36.9% during the 4th quarter. Smartleaf Asset Management LLC now owns 590 shares of the medical equipment provider’s stock valued at $43,000 after purchasing an additional 159 shares in the last quarter. Trivant Custom Portfolio Group LLC raised its position in Hologic by 2.1% during the 4th quarter. Trivant Custom Portfolio Group LLC now owns 8,348 shares of the medical equipment provider’s stock valued at $602,000 after purchasing an additional 169 shares in the last quarter. Finally, Loomis Sayles & Co. L P raised its position in Hologic by 29.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 808 shares of the medical equipment provider’s stock valued at $66,000 after purchasing an additional 183 shares in the last quarter. Hedge funds and other institutional investors own 94.73% of the company’s stock.

Analyst Ratings Changes

HOLX has been the subject of a number of research analyst reports. Wolfe Research initiated coverage on Hologic in a research report on Friday, December 13th. They set a “peer perform” rating for the company. Leerink Partners downgraded Hologic from an “outperform” rating to a “market perform” rating and cut their price target for the company from $80.00 to $75.00 in a report on Thursday, February 6th. Needham & Company LLC lowered Hologic from a “buy” rating to a “hold” rating and set a $90.00 target price on the stock. in a research report on Monday, February 3rd. William Blair reaffirmed an “outperform” rating on shares of Hologic in a research report on Thursday, February 6th. Finally, BNP Paribas raised Hologic to a “strong-buy” rating in a research report on Tuesday, December 10th. Eleven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, Hologic currently has a consensus rating of “Hold” and a consensus target price of $84.62.

Hologic Stock Up 0.3 %

Shares of NASDAQ HOLX opened at $61.98 on Wednesday. The company has a debt-to-equity ratio of 0.52, a current ratio of 3.49 and a quick ratio of 2.78. The business has a 50-day moving average of $66.72 and a two-hundred day moving average of $74.37. Hologic, Inc. has a 1 year low of $60.34 and a 1 year high of $84.67. The company has a market capitalization of $13.91 billion, a price-to-earnings ratio of 19.55, a price-to-earnings-growth ratio of 2.14 and a beta of 0.97.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.02 by $0.01. Hologic had a return on equity of 19.72% and a net margin of 18.42%. On average, analysts forecast that Hologic, Inc. will post 4.28 earnings per share for the current fiscal year.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.